Related Experiment Video
Updated: Mar 7, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: a systematic review and
Hasib Hanif1,2, Emilie P Belley-Cote1, Abdullah Alotaibi1,2
1Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada.
Insights
Left atrial appendage (LAA) occlusion shows promise for stroke prevention in atrial fibrillation (AF) patients, potentially offering benefits similar to oral anticoagulation. However, current evidence quality is low, necessitating further research.
Area of Science:
- Cardiology
- Interventional Cardiology
- Stroke Prevention
Background:
- Atrial fibrillation (AF) is a primary cause of stroke, with oral anticoagulation (OAC) therapy often limited by bleeding risks.
- Left atrial appendage (LAA) occlusion presents an alternative stroke prevention strategy for AF patients.
- Network meta-analysis (NMA) is employed to compare LAA occlusion with existing therapies.
Purpose of the Study:
- To evaluate the efficacy of LAA occlusion versus oral anticoagulants, antiplatelets, and placebo for stroke prevention in AF patients.
- To assess the impact of LAA occlusion on mortality, major bleeding, and operative time.
- To compare LAA occlusion with standard treatments using a network meta-analysis.
Main Methods:
- Systematic search of MEDLINE, EMBASE, PubMed, and Cochrane Library for relevant randomized trials.
- Inclusion of trials comparing percutaneous or surgical LAA occlusion with standard of care in AF patients.
- Network meta-analysis to synthesize evidence and compare treatment effects.
Main Results:
- Conventional meta-analysis showed no significant difference in stroke rates but a significant reduction in mortality favoring LAA occlusion.
- NMA indicated a trend towards reduced stroke and mortality with LAA occlusion versus warfarin, though not statistically significant.
- LAA occlusion ranked highest for efficacy in stroke and mortality prevention compared to warfarin, aspirin, or placebo, with low-quality evidence.
Conclusions:
- LAA occlusion may offer comparable stroke prevention benefits to OAC therapy in AF patients.
- The current evidence supporting LAA occlusion is of low quality, requiring cautious interpretation.
- Further high-quality research is needed to confirm the efficacy and safety of LAA occlusion.
Introduction:
Atrial fibrillation (AF) is one of the leading causes of stroke. Risks associated with oral anticoagulation (OAC) limit adherence to recommended therapy. Left atrial appendage (LAA) occlusion is a treatment alternative in patients with AF. We performed a network meta-analysis (NMA) of randomized trials evaluating the efficacy of LAA occlusion compared with oral anticoagulant, antiplatelet, and placebo for stroke prevention. We also assessed the impact of LAA occlusion on mortality, major bleeding, and operative time.
Evidence Acquisition:
We searched MEDLINE, EMBASE, PubMed, and Cochrane Library for randomized trials comparing percutaneous or surgical LAA occlusion with standard of care in AF patients.
Evidence Synthesis:
Conventional meta-analysis found no difference between groups for stroke (5 trials, 1285 patients;RR 0.78, 95% CI 0.47-1.29), and a significant reduction in mortality (5 trials, 1285 patients; RR 0.71, 95% CI 0.51-0.99) favouring LAA occlusion. NMA demonstrated a trend towards reduction in stroke (OR 0.84, 95% CrI 0.47-1.55) and mortality (OR 0.69, 95% CrI 0.44-1.10) for LAA occlusion versus warfarin, but no statistically significant effect. Statistical ranking curves placed LAA occlusion as the most efficacious treatment on the outcomes of stroke and mortality when compared to warfarin, aspirin, or placebo. No significant differences between groups were seen in major bleeding or operative time for surgical trials. The overall quality of the evidence was low as assessed by GRADE.
Conclusions:
LAA occlusion appears to preserve the benefits of OAC therapy for stroke prevention in patients with AF, but the current evidence is of low quality.
